Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET
Company Participants
Jon Patton - Director, IR & Communication
Matt Coffey - CEO
Tom Heineman - CMO
Andrew de Guttadauro - Global Head, Business Development
Kirk Look - CFO
Conference Call Participants
John Newman - Canaccord
Operator
Good morning, and welcome to Oncolytics Biotech's Third Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the Company's request.
I now would like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead, sir.
Jon Patton
Thank you, operator, and good morning everyone.
Earlier this morning, Oncolytics issued two press releases, one announcing interim results from the pancreatic cancer cohort of the company's Phase 1/2 GOBLET trial and a second providing recent operational highlights and financial results for the third quarter of 2022. The announcements and highlights provided in these press releases will be the topics of today's call.
A replay of this will be available on the Events & Presentations section of the Oncolytics website approximately two hours after its completion. After remarks from Company management we will open the call for Q&A.
As a reminder, various remarks made during this call contain certain forward-looking statements relating to the Company's business prospects and the development and commercialization of pelareorep, including statements regarding the Company's focus, strategy and objectives, Company's belief as to the potential and mode of action of pelareorep as a cancer therapeutic, design, aims and anticipated benefits of the current -- company's current and in clinical trials and anticipated timing of the release of the additional data, Company's plans and expectations regarding potential registrational study, Company's business development plans and strategies and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors, which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control that may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.
In any forward-looking statements in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that these statement or expectation or belief will be achieved.